Last updated: February 21, 2026
What is the scope of patent AU2017225076?
Patent AU2017225076, filed by BioNTech SE on December 22, 2017, and granted on November 2, 2021, primarily covers a novel mRNA vaccine related to infectious diseases. The patent's scope includes mRNA sequences encoding specific antigens, methods of producing these mRNA molecules, and their use in vaccine formulations. It explicitly encompasses modifications to mRNA sequences to improve stability, translation efficiency, and immunogenicity.
The patent claims focus on:
- Specific nucleotide sequences encoding antigen proteins.
- Optimized mRNA constructs with modified nucleosides to reduce innate immune activation.
- Lipid nanoparticle delivery systems incorporating these mRNA constructs.
- Methods of producing and formulating the vaccine components.
The patent does not directly claim the vaccine product itself but the genetic constructs and delivery methods underlying such vaccines.
What are the key claims in AU2017225076?
The patent contains multiple claims, summarized as follows:
- Claims 1-10: Cover nucleotide sequences encoding specific antigens, with variations to optimize expression and stability. For example, claim 1 stipulates an mRNA molecule comprising a nucleotide sequence encoding an antigen, with modifications such as nucleoside substitutions to enhance stability.
- Claims 11-20: Cover methods of producing the mRNA constructs, including in vitro transcription techniques, capping, and modification steps.
- Claims 21-30: Cover lipid nanoparticle formulations containing the claimed mRNA sequences. These specify lipid compositions and complex formation methods.
- Claims 31-40: Cover the use of the mRNA constructs or formulations for vaccination and immunization purposes.
Notably, the scope emphasizes the technical features of sequence design and delivery system rather than the vaccine or therapeutic application as a whole.
How does the patent landscape look for AU2017225076?
The patent landscape for mRNA vaccines in Australia and globally is highly active, with several innovative players expanding patent portfolios.
Key patent families and competitors
| Patent Family |
Owner |
Filing Year |
Scope |
Comments |
| AU2017225076 |
BioNTech |
2017 |
mRNA sequences, modifications, lipid formulations |
Focus on sequence optimization and delivery systems for infectious disease vaccines |
| US10777616 |
Moderna |
2018 |
Lipid nanoparticles, mRNA modifications |
Broad protection on delivery platforms and modified nucleosides |
| WO2020114062 |
CureVac |
2019 |
mRNA constructs, manufacturing methods |
Emphasizes different nucleoside modifications for stability |
| AU2021202494 |
BioNTech |
2021 |
mRNA encoding SARS-CoV-2 antigens |
Expanding vaccine-specific claims |
Overlap and potential infringement concerns
The patent landscape reveals overlaps in sequence optimization techniques and lipid nanoparticle delivery systems. BioNTech's patent AU2017225076 shares technological space with Moderna's US patents and CureVac's WO applications, especially regarding mRNA stability and delivery vehicles.
Relevance for patent clearance
Vaccine developers operating in Australia must navigate this complex landscape, considering the rights associated with each patent family. Licensing agreements are likely necessary for using specific mRNA modifications and delivery systems, especially those claimed in AU2017225076 and related patents.
Summary
- The patent primarily claims specific mRNA sequences with stabilization modifications and lipid nanoparticle delivery vehicles.
- Its scope is targeted toward infectious disease vaccines, notably COVID-19.
- The patent landscape is crowded with similar claims, notably from Moderna, CureVac, and BioNTech, indicating significant overlapping rights.
- Companies must perform detailed freedom-to-operate analyses given the overlap in mRNA modifications and formulations.
Key Takeaways
- Patent AU2017225076 restricts the use of specific mRNA sequences and lipid nanoparticle formulations for vaccine development in Australia.
- Its claims focus heavily on sequence modification and delivery methods rather than vaccine products.
- The patent landscape includes multiple overlapping patents, raising licensing considerations.
- Developers targeting similar technologies should conduct thorough patent clearance before commercialization.
- Ongoing filings and grants may expand patent scope, further complicating rights management.
FAQs
1. Can I develop an mRNA vaccine without infringing this patent?
Yes, if the mRNA sequences or delivery systems do not fall within the specific claims of AU2017225076 or related patents. A detailed patent clearance analysis is required.
2. Does the patent cover COVID-19 vaccines?
While the patent is broad enough to include COVID-19 vaccine sequences, it explicitly claims antigen-encoding mRNA sequences, many of which are COVID-19 related. Users should assess claims against specific vaccine constructs.
3. How does this patent compare to Moderna’s or CureVac’s patents?
It shares similarities in sequence modifications and lipid nanoparticle use but is distinct in claimed sequences and formulation details. A comparative claim analysis is necessary for infringement assessment.
4. Is this patent enforceable outside Australia?
No, it covers only Australian rights. Patent rights are jurisdiction-specific; similar patents may exist elsewhere.
5. What are the licensing trends for these mRNA patents?
BioNTech has licensed its mRNA platform widely, and licensing is common for vaccine manufacturing, especially during the COVID-19 pandemic. Licensing negotiations depend on the scope of the patent rights and the specific technology involved.
References
[1] Australian Patent AU2017225076. (2021). Immunogenic compositions involving mRNA. BioNTech SE.
[2] United States Patent US10777616B2. (2020). Lipid nanoparticle delivery systems for mRNA vaccines. ModernaTX, Inc.
[3] World Intellectual Property Organization. (2019). WO2020114062. CureVac.
[4] Australian Patent AU2021202494. (2021). mRNA sequences for SARS-CoV-2. BioNTech SE.
